PACTG 1034: PROTEASE-CONTAINING AND PROTEASE-SPARING HAART REGIMENS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 设计：III期、开放标签、随机 样本量：240例受试者 人口：受艾滋病毒感染的青少年，无论感染途径如何，年龄在13至23岁之间，艾滋病毒RNA > 10，000拷贝/毫升，受试者的初级保健提供者认为需要对其进行抗逆转录病毒治疗。受试者可能从未接受过抗逆转录病毒治疗，或可能接受过单一联合治疗方案，包括NRTI联合或不联合单一PI（洛匹那韦除外）。 除了妊娠期间ZDV单药治疗外，她们一生中可能未接受过超过一种治疗方案。 受试者必须从未接受过非核苷类逆转录酶抑制剂（NNRTI）治疗。 分层：所有受试者将按照既往抗逆转录病毒暴露（绝对未暴露或抗逆转录病毒暴露）进行分层。 研究持续时间：96周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESIGN: Phase III, open-label, randomized SAMPLE SIZE: 240 subjects POPULATION: HIV-infected adolescents, regardless of route of infection, who are 13 to 23 years of age with HIV RNA >10,000 copies/ml and for whom antiretroviral treatment is felt to be indicated by a subject's primary care provider. Subjects may be nanve to antiretroviral therapy, or may have received a single regimen of combination therapy, consisting of NRTIs with or without a single PI (except lopinavir). They may not have received more than a single regimen in their lifetime with the exception of ZDV monotherapy during pregnancy. Subjects must be nanve to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. STRATIFICATION: All subjects will be stratified by previous antiretroviral exposure (absolutely nanve or antiretroviral exposed). DURATION OF STUDY: Ninety-six weeks.